Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT)
Conditions
Interventions
Verekitug (UPB-101)
Placebo
Locations
41
United States
Sensa Health LA (Sensa Health Clinical Research)
Los Angeles, California, United States
NewportNativeMD, Inc.
Newport Beach, California, United States
DaVinci, Research LLC
Roseville, California, United States
Senta Clinic
San Diego, California, United States
University of Missouri
Columbus, Colorado, United States
Western States Clinical Research, Inc.
Wheat Ridge, Colorado, United States
Start Date
December 18, 2023
Primary Completion Date
July 7, 2025
Completion Date
July 22, 2025
Last Updated
August 15, 2025
NCT06914908
NCT05246267
NCT07125586
NCT06118554
NCT05708300
NCT07424144
Lead Sponsor
Upstream Bio Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions